F. Gamarra (Munich, Germany), G. Hardavella (Athens, Greece)
LATE-BREAKING ABSTRACT: Effect of training on maximal oxygen uptake and muscular strength after lung cancer surgery - A randomized controlled trial E. Edvardsen, O. H. Skjonsberg, F. Borchsenius, S. A Anderssen (Oslo, Norway)
| |
Cetuximab administered through pulmonary route in a mice model of lung tumor L. Guilleminault, F. Paul, S. Lerondel, V. Schubnel, J. Montharu, M. De Monte, A. Lepape, E. Lemarié, N. Heuzé-Vourc'h (Tours, Orléans, France)
| |
LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung Y. L. Wu, C. Zhou, C. P. Hu, J. Feng, S. Lu, Y. Huang, W. Li, M. Hou, J. H. Shi, K. Y. Lee, D. Massey, Y. Shi, J. J. Chen, V. Zazulina, S. L. Geater (Guangzhou, Shanghai, Changsha, Nanjing, Kunming, Changchun, Chengdu, Linyi, China; Seoul, Republic Of Korea; Bracknell, United Kingdom; Songkhla, Thailand)
| |
Ifosfamide (IFO) is a valuable alternative to cisplatin (CDDP) for first-line chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC): A meta-analysis T. Berghmans, M. Paesmans, A. P. Meert, M. Tiseo, J. P. Sculier (Brussels, Belgium; Parma, Italy)
| |
Pemetrexed in advanced non-small cell lung cancer patients with idiopathic pulmonary fibrosis M. Kato, T. Shukuya, F. Takahashi, A. Inagaki, R. Kanemaru, R. Ko, S. Yagishita, N. Fariz, I. Kobayashi, A. Murakami, Y. Hoshika, K. Muraki, R. Koyama, N. Shimada, A. Sakuraba, K. Takahashi (Japan)
| |
Treatment of advanced non-small cell lung cancer with trofosfamide A. Reissig, M. Walther (Jena, Germany)
| |
CyberKnife radiosurgery for early stage nonsmall cell lung cancer B. Komurcuoglu, A. Olmezoglu, H. Koparal, E. Yalniz (Izmir, Turkey)
| |
The role of second line chemotherapy in small cell lung cancer: A retrospective analysis E. Boutsikou, P. Zarogoulidis, K. Porpodis, D. Latsios, M. Kipourou, K. Zarogoulidis (Thessaloniki, Greece)
| |